Alaunos (TCRT) news

Trading released/resumed: (TCRT) Reason not available

Trading in shares of Alaunos Therapeutics, Inc. (TCRT) has resumed following an unspecified suspension, according to recent market updates. No official reason has been provided for the prior halt in trading activity. Investors are advised to monitor further announcements from the company or…

Trading halted: (TCRT) Due to limit-up limit-down trading pause

Trading in shares of TCRT was temporarily suspended on October 13, 2026, due to the activation of the Securities and Exchange Commission’s Limit Up-Limit Down (LULD) mechanism. The rule is designed to prevent excessive price volatility by restricting trades outside predefined price bands based on…

Alaunos Therapeutics: Prices $350 mln PIPE offering of 687,789 common shares at $1.44 and 243,063 series C preferred at $1,435.70 - SEC filing

Alaunos Therapeutics - Buys Velaris Therapeutics on October 13, 2026 - SEC filing

On October 13, 2026, Alaunos Therapeutics (NASDAQ: TCRT) announced the acquisition of Velaris Therapeutics, a move disclosed in a recent SEC filing. The acquisition, detailed in a Form 8-K submitted on October 9, 2026, marks a significant strategic development for the biopharmaceutical company. The…

Alaunos Therapeutics, Inc. announces pricing of registered direct offering priced at-the-market under Nasdaq rules

Alaunos Therapeutics, Inc. (TCRT) has announced the pricing of a registered direct offering conducted at-the-market under Nasdaq rules. The offering is part of the company's ongoing efforts to raise capital, with shares being sold directly to institutional investors. No specific details regarding…